Dr. Rabinowe studies essential hypertension (a type of high blood pressure without a known cause), Type 1 diabetes, and iron overload conditions. In her research, she explores how the body reacts to sodium and hormones, which are crucial in managing hypertension. She also investigates treatments that can improve insulin control in new diabetes patients and therapies to remove excess iron in patients who have received frequent blood transfusions, aiming to enhance their overall health and reduce complications.
Key findings
In patients with essential hypertension, those who poorly manage sodium retained more sodium and took about 36.6 hours to balance their sodium levels, compared to 23.9 hours in healthy individuals.
For patients with recent onset Type 1 diabetes, 80% of those treated with anti-thymocyte globulin and prednisone used less than 0.2 units of insulin per kilogram per day, indicating better blood sugar control.
Long-term treatment with deferoxamine for patients with transfusion-related iron overload led to improved liver density in 80% of patients, some even experiencing normalized liver function over a period of up to 66 months.
Administering enalapril improved kidney blood flow in patients with essential hypertension who normally do not respond to sodium intake, leading to better management of their blood pressure.
Frequently asked questions
Does Dr. Rabinowe study high blood pressure?
Yes, she researches essential hypertension and how the body manages sodium, which directly affects blood pressure.
What treatments has Dr. Rabinowe researched for diabetes?
She has studied the effects of anti-thymocyte globulin and prednisone in patients with recent onset Type 1 diabetes, showing they can achieve better blood sugar control.
Is Dr. Rabinowe's work relevant to patients with iron overload?
Yes, her research on deferoxamine therapy is specifically aimed at helping patients with excess iron due to blood transfusions.
How does Dr. Rabinowe's research help patients with essential hypertension?
Her findings identify specific treatments like enalapril that can improve kidney function and blood pressure in certain groups of hypertensive patients.
Publications in plain English
Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II.
1986
The American journal of medicine
Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S +1 more
Plain English This study looked at how patients with essential hypertension (high blood pressure without a clear cause) handle sodium in their bodies. Researchers found that in a group of 32 patients who had abnormal responses to a hormone called angiotensin II, it took them longer (about 36.6 hours) to balance their sodium levels compared to healthy individuals (about 23.9 hours) and those with normal responses (about 24.5 hours), showing they retained more sodium and gained weight when sodium intake increased. This matters because the differences in how these patients process sodium may contribute to their high blood pressure, highlighting the need for tailored treatment strategies.
Who this helps: This helps patients with essential hypertension who may need better management of their sodium intake.
Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.
1985
The Journal of clinical investigation
Redgrave J, Rabinowe S, Hollenberg NK, Williams GH
Plain English This study looked at how a medication called enalapril affects blood flow in the kidneys of patients with high blood pressure, especially focusing on those whose kidneys do not respond normally to sodium intake. In 25 patients with essential hypertension, those that typically do not show increased blood flow after eating salty foods (nonmodulators) experienced a significant improvement after taking enalapril, leading to better kidney blood flow and reduced blood pressure, while those who do respond normally (modulators) showed no change. These findings are important because they indicate that enalapril can help a specific group of high blood pressure patients by normalizing their kidney responses, potentially leading to better management of their condition.
Who this helps: This helps patients with essential hypertension who do not respond well to sodium intake.
Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
1985
Archives of internal medicine
Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG +1 more
Plain English This study looked at how effective a long-term treatment called deferoxamine is for adults who have too much iron in their bodies due to blood transfusions. The researchers treated six patients for up to 66 months and found that four out of five had decreased liver density, and in some cases, liver function improved or normalized. Overall, this treatment helped prevent further damage to organs and even reversed some issues, which is important for maintaining health in these patients.
Who this helps: This benefits patients with iron overload from blood transfusions.
Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.
1985
Diabetes research (Edinburgh, Scotland)
Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R +2 more
Plain English The study looked at how two treatments, anti-thymocyte globulin (ATGAM) and prednisone, affect people who recently developed Type 1 diabetes. Researchers found that patients who received ATGAM and prednisone had better blood sugar control, needing significantly less insulin—specifically, 4 out of 5 patients used less than 0.2 units of insulin per kilogram per day. This is important because it shows that these treatments could lead to improved management of diabetes and possibly even longer periods without needing insulin.
Who this helps: This helps patients with recent onset Type 1 diabetes.